Business Context and Reporting Period
This Form 8-K is a current report filed by Globus Medical, Inc. on May 17, 2017, regarding an event that occurred on May 15, 2017. The filing addresses regulatory developments concerning the Company's ExcelsiusGPS robotic guidance and navigation system.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It solely reaffirms the Company's full-year 2017 financial guidance:
- Full Year 2017 Sales Guidance: $625 million
- Full Year 2017 Non-GAAP Fully Diluted EPS Guidance: $1.27
Material Changes
The primary material change reported is a delay in the anticipated regulatory clearance for the ExcelsiusGPS system:
- Previous Expectation: The Company previously estimated likely FDA clearance in the second calendar quarter of 2017.
- Current Status: The FDA informed the Company that its 510(k) submission did not sufficiently address regulatory questions within the required review period.
- Revised Timeline: The Company no longer anticipates obtaining FDA clearance for ExcelsiusGPS during the second calendar quarter of 2017.
- Next Steps: The Company intends to file a revised 510(k) submission in an expedited fashion.
Guidance, Outlook, and Risks
Management Commentary: Despite the regulatory delay, management remains confident in its ability to satisfy the issues identified by the FDA. The Company has explicitly reaffirmed its full-year 2017 sales and earnings per share guidance.
Risks and Contingencies: The filing includes a standard cautionary note regarding forward-looking statements. Key risks cited include the ability to comply with laws and regulations, the success of new product development, and the ability to convince surgeons to use the Company's products. The Company notes that actual results could differ materially from predictions due to these uncertainties.
Investor Verification Checklist
- Verify the timeline for the revised 510(k) submission and potential new clearance dates.
- Monitor future filings for updates on the FDA's response to the revised submission.
- Assess the potential impact of the ExcelsiusGPS delay on the Company's ability to meet the reaffirmed $625 million sales guidance.
- Review the most recent Form 10-K and 10-Q for detailed risk factors regarding regulatory approvals and product adoption.